Phase 1Completed

Assessment of Abuse Potential of Rapastinel in Humans

A Two-part, Single-dose, Randomized, Double-blind, Placebo and Active-Controlled Crossover Study to Evaluate the Abuse Potential of Rapastinel in Healthy, Non-dependent, Adult Recreational Polydrug Users

Sponsor
Naurex, Inc, an affiliate of Allergan plc (Industry)
Enrollment
72 enrolled
Conditions
Human Abuse Potential
Interventions
Rapastinel; Ketamine; Placebo
Ages
adults
Registry
NCT03799900

Full record on ClinicalTrials.gov

From the registry

Based on the pharmacological class of rapastinel, this study will be conducted to evaluate the abuse potential of single doses of rapastinel as compared with ketamine, a NMDAR antagonist that is a Schedule III dissociative anesthetic, and placebo in recreational polydrug users.

Primary outcomes

  • Maximum effect (Emax) for "At this Moment" Drug Liking visual analog scale (VAS).

History

  1. Last registry update

  2. Study completion

  3. Primary completion

  4. Registered

  5. Started